Nektar Therapeutics Total Liabilities and Share Holders Equity 2010-2024 | NKTR

Nektar Therapeutics total liabilities and share holders equity from 2010 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Nektar Therapeutics Annual Total Liabilities and Share Holders Equity
(Millions of US $)
2023 $398
2022 $711
2021 $1,117
2020 $1,539
2019 $1,977
2018 $2,150
2017 $509
2016 $569
2015 $499
2014 $442
2013 $435
2012 $498
2011 $607
2010 $521
2009 $576
Nektar Therapeutics Quarterly Total Liabilities and Share Holders Equity
(Millions of US $)
2024-09-30 $308
2024-06-30 $343
2024-03-31 $396
2023-12-31 $398
2023-09-30 $442
2023-06-30 $494
2023-03-31 $562
2022-12-31 $711
2022-09-30 $781
2022-06-30 $862
2022-03-31 $1,024
2021-12-31 $1,117
2021-09-30 $1,277
2021-06-30 $1,371
2021-03-31 $1,457
2020-12-31 $1,539
2020-09-30 $1,509
2020-06-30 $1,595
2020-03-31 $1,888
2019-12-31 $1,977
2019-09-30 $2,088
2019-06-30 $2,100
2019-03-31 $2,166
2018-12-31 $2,150
2018-09-30 $2,249
2018-06-30 $2,313
2018-03-31 $497
2017-12-31 $509
2017-09-30 $582
2017-06-30 $476
2017-03-31 $528
2016-12-31 $569
2016-09-30 $425
2016-06-30 $463
2016-03-31 $492
2015-12-31 $499
2015-09-30 $449
2015-06-30 $457
2015-03-31 $499
2014-12-31 $442
2014-09-30 $477
2014-06-30 $478
2014-03-31 $487
2013-12-31 $435
2013-09-30 $383
2013-06-30 $413
2013-03-31 $448
2012-12-31 $498
2012-09-30 $541
2012-06-30 $668
2012-03-31 $695
2011-12-31 $607
2011-09-30 $648
2011-06-30 $671
2011-03-31 $704
2010-12-31 $521
2010-09-30 $502
2010-06-30 $531
2010-03-31 $549
2009-12-31 $576
2009-09-30 $453
2009-06-30 $473
2009-03-31 $506
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.165B $0.090B
Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $74.844B 28.80
Chugai Pharmaceutical (CHGCY) Japan $70.231B 27.36
Takeda Pharmaceutical (TAK) Japan $41.110B 8.56
Sandoz Group AG (SDZNY) Switzerland $19.633B 0.00
Merck (MKKGY) Germany $18.831B 16.86
Astellas Pharma (ALPMY) Japan $17.264B 15.90
United Therapeutics (UTHR) United States $16.024B 15.76
Neurocrine Biosciences (NBIX) United States $14.505B 38.41
Summit Therapeutics (SMMT) United States $14.034B 0.00
Shionogi (SGIOY) Japan $12.114B 12.14
Orion OYJ (ORINY) Finland $7.195B 20.23
Stevanato Group S.p.A (STVN) Italy $6.920B 44.80
Madrigal Pharmaceuticals (MDGL) United States $6.404B 0.00
Corcept Therapeutics (CORT) United States $5.795B 43.90
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.456B 0.00
Grifols, S.A (GRFS) Spain $4.999B 0.00
Ionis Pharmaceuticals (IONS) United States $4.963B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.464B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.717B 12.31
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.559B 15.30
Recursion Pharmaceuticals (RXRX) United States $2.551B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.176B 0.00
Soleno Therapeutics (SLNO) United States $2.021B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.999B 0.00
Hypermarcas (HYPMY) Brazil $1.932B 0.00
Indivior (INDV) United States $1.606B 6.54
BioCryst Pharmaceuticals (BCRX) United States $1.543B 0.00
Evotec AG (EVO) Germany $1.456B 0.00
Dyne Therapeutics (DYN) United States $1.438B 0.00
Xencor (XNCR) United States $1.346B 0.00
Guardian Pharmacy Services (GRDN) United States $1.310B 0.00
Ocular Therapeutix (OCUL) United States $1.259B 0.00
ARS Pharmaceuticals (SPRY) United States $1.222B 0.00
Harrow (HROW) United States $1.206B 0.00
Ardelyx (ARDX) United States $1.187B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.147B 0.00
Collegium Pharmaceutical (COLL) United States $1.076B 5.87
Enliven Therapeutics (ELVN) United States $1.049B 0.00
Bioventus (BVS) United States $0.815B 25.74
Cronos Group (CRON) Canada $0.761B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.747B 0.00
Relay Therapeutics (RLAY) United States $0.747B 0.00
USANA Health Sciences (USNA) United States $0.648B 12.02
Ironwood Pharmaceuticals (IRWD) United States $0.586B 0.00
Elite Pharmaceuticals (ELTP) United States $0.526B 0.00
Verve Therapeutics (VERV) United States $0.520B 0.00
Savara (SVRA) United States $0.503B 0.00
Altimmune (ALT) United States $0.488B 0.00
ProKidney (PROK) United States $0.484B 0.00
Xeris Biopharma Holdings (XERS) United States $0.477B 0.00
Tourmaline Bio (TRML) United States $0.462B 0.00
OmniAb (OABI) United States $0.453B 0.00
Akebia Therapeutics (AKBA) United States $0.452B 0.00
Siga Technologies (SIGA) United States $0.444B 5.19
Esperion Therapeutics (ESPR) United States $0.435B 0.00
Zevra Therapeutics (ZVRA) United States $0.430B 0.00
Oruka Therapeutics (ORKA) United States $0.429B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.422B 0.00
Organogenesis (ORGO) United States $0.420B 0.00
KalVista Pharmaceuticals (KALV) United States $0.410B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.355B 143.79
Korro Bio (KRRO) United States $0.347B 0.00
Aldeyra Therapeutics (ALDX) United States $0.288B 0.00
Aquestive Therapeutics (AQST) United States $0.283B 0.00
Nature's Sunshine Products (NATR) United States $0.264B 15.68
Heron Therapeutics (HRTX) United States $0.248B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.247B 0.00
Avita Medical (RCEL) United States $0.227B 0.00
Profound Medical (PROF) Canada $0.221B 0.00
Larimar Therapeutics (LRMR) United States $0.213B 0.00
4D Molecular Therapeutics (FDMT) United States $0.212B 0.00
MediWound (MDWD) Israel $0.190B 0.00
Inhibikase Therapeutics (IKT) United States $0.189B 0.00
CytoDyn (CYDY) United States $0.185B 0.00
Aclaris Therapeutics (ACRS) United States $0.184B 0.00
Acrivon Therapeutics (ACRV) United States $0.180B 0.00
VAXART, INC (VXRT) United States $0.168B 0.00
Lyell Immunopharma (LYEL) United States $0.168B 0.00
Lexeo Therapeutics (LXEO) United States $0.168B 0.00
Silence Therapeutics (SLN) United Kingdom $0.153B 0.00
Jupiter Neurosciences (JUNS) United States $0.146B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.145B 0.00
Nanobiotix S.A (NBTX) France $0.143B 0.00
Telomir Pharmaceuticals (TELO) United States $0.139B 0.00
Champions Oncology (CSBR) United States $0.135B 0.00
Cassava Sciences (SAVA) United States $0.132B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.111B 0.00
Inotiv (NOTV) United States $0.111B 0.00
Achieve Life Sciences (ACHV) Canada $0.106B 0.00
ElectroCore (ECOR) United States $0.104B 0.00
Cardiol Therapeutics (CRDL) Canada $0.099B 0.00
Metagenomi (MGX) United States $0.098B 0.00
Protara Therapeutics (TARA) United States $0.094B 0.00
Pyxis Oncology (PYXS) United States $0.089B 0.00
Fractyl Health (GUTS) United States $0.087B 0.00
Arch Biopartners (ACHFF) Canada $0.085B 0.00
Karyopharm Therapeutics (KPTI) United States $0.083B 0.00
Regulus Therapeutics (RGLS) United States $0.081B 0.00
Assertio Holdings (ASRT) United States $0.079B 20.68
Galectin Therapeutics (GALT) United States $0.078B 0.00
ESSA Pharma (EPIX) Canada $0.078B 0.00
Century Therapeutics (IPSC) United States $0.077B 0.00
Journey Medical (DERM) United States $0.076B 0.00
Context Therapeutics (CNTX) United States $0.076B 0.00
Vivani Medical (VANI) United States $0.071B 0.00
PMV Pharmaceuticals (PMVP) United States $0.071B 0.00
Avalo Therapeutics (AVTX) United States $0.070B 0.00
Mural Oncology (MURA) Ireland $0.068B 0.00
AleAnna (ANNA) United States $0.065B 0.00
Unicycive Therapeutics (UNCY) United States $0.064B 0.00
OptiNose (OPTN) United States $0.064B 0.00
Gain Therapeutics (GANX) United States $0.060B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.059B 0.00
Prelude Therapeutics (PRLD) United States $0.058B 0.00
FibroGen (FGEN) United States $0.058B 0.00
Rafael Holdings (RFL) United States $0.050B 0.00
NRx Pharmaceuticals (NRXP) United States $0.049B 0.00
AlloVir (ALVR) United States $0.047B 0.00
Nutriband (NTRB) United States $0.046B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.044B 0.00
SCYNEXIS (SCYX) United States $0.043B 0.00
Iterum Therapeutics (ITRM) Ireland $0.042B 0.00
CASI Pharmaceuticals (CASI) China $0.041B 0.00
Scienture Holdings (SCNX) United States $0.040B 0.00
Tempest Therapeutics (TPST) United States $0.040B 0.00
VYNE Therapeutics (VYNE) United States $0.040B 0.00
BioVie (BIVI) United States $0.040B 0.00
Surrozen (SRZN) United States $0.039B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.036B 0.00
Incannex Healthcare (IXHL) Australia $0.034B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.031B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.030B 0.00
Citius Pharmaceuticals (CTXR) United States $0.028B 0.00
Vivos Therapeutics (VVOS) United States $0.028B 0.00
DURECT (DRRX) United States $0.026B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.026B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
Enlivex Therapeutics (ENLV) Israel $0.024B 0.00
Lipocine (LPCN) United States $0.023B 0.00
Traws Pharma (TRAW) United States $0.022B 0.00
Mannatech (MTEX) United States $0.021B 0.00
Cosmos Health (COSM) United States $0.020B 0.00
MEI Pharma (MEIP) United States $0.019B 0.00
Carisma Therapeutics (CARM) United States $0.018B 0.00
GlycoMimetics (GLYC) United States $0.017B 0.00
PolyPid (PYPD) Israel $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.016B 0.00
ProPhase Labs (PRPH) United States $0.014B 0.00
Lyra Therapeutics (LYRA) United States $0.012B 0.00
TherapeuticsMD (TXMD) United States $0.012B 0.00
Biomerica (BMRA) United States $0.012B 0.00
Nuvilex (PMCB) United States $0.012B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.012B 0.00
Talphera (TLPH) United States $0.011B 0.00
Relmada Therapeutics (RLMD) United States $0.011B 0.00
Jaguar Animal Health (JAGX) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
Klotho Neurosciences (KLTO) United States $0.009B 0.00
Indaptus Therapeutics (INDP) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
BioLineRx (BLRX) Israel $0.008B 0.00
Dominari Holdings (DOMH) United States $0.008B 0.00
Conduit Pharmaceuticals (CDT) United States $0.007B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.007B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
Viracta Therapeutics (VIRX) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
SciSparc (SPRC) Israel $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
Phio Pharmaceuticals (PHIO) United States $0.004B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.10
InMed Pharmaceuticals (INM) Canada $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
Bio-Path Holdings (BPTH) United States $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
SHINECO (SISI) China $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.003B 0.00
TransCode Therapeutics (RNAZ) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Aditxt (ADTX) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00